INDIANAPOLIS , Feb. 4, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, March 15, 2021 to provide an update on its Alzheimer's disease program and discuss results from the Phase 2 TRAILBLAZER-ALZ study for donanemab being presented at the 15th International
investor.lilly.com
investor.lilly.com
